Does prolonged QTc predict pulmonary involvement in COVID-19 patients?

Year 2023, Volume: 9 Issue: 6 - November 2023, 1321 - 1326, 04.11.2023

Aydın Sarıhan , Ömer Faruk Rahman , Serhat Koran , Fatih Aytemiz , Çağdaş Can , Fatih Rahman , Emre Bulbul

https://doi.org/10.18621/eurj.1226077

Abstract

Objectives: Coronavirus disease (COVID-19) is a disease with high mortality due to acute respiratory distress syndrome (ARDS) secondary to viral pneumonia. In addition to its effects on the respiratory system, coronavirus is known to have serious systemic effects on the cardiovascular system. In this study, we aimed to investigate the association between prolonged QTc duration and COVID-19 specific pulmonary involvement

Methods: Between December 2020 and February 2021, 112 patients who were diagnosed with COVID-19 in our COVID-19 outpatient clinic and met the inclusion criteria were evaluated for the association between cardiac variables (heart rate, PR width, QRS width, fQRS, and QTc interval), other patient characteristics and lung involvement.

Results: A significant difference was found between the QTc intervals of COVID-19 patients with and without lung involvement (p < 0.026). In the ROC analysis for the QTc interval, which was found to be significant in the multivariate regression analysis, the cut-off value of 419.5 ms had a sensitivity of 72% and a specificity of 51.6% in predicting pulmonary involvement.

Conclusions: Prolonged QTc duration may be useful in predicting COVID-19 pulmonary involvement in patients admitted to the emergency department.

Keywords

COVID-19, electrocardiography, prolonged QTc, pulmonary involvement

References

• 1. World Health Organization, 2021. The impact of COVID-19 on health and care workers: a closer look at deaths (No. WHO/HWF/WorkingPaper/2021.1). World Health Organization.
• 2. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020;116:1666-87.
• 3. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, et al. COVID-19 and cardiovascular disease. Circulation 2020;141:1648-55.
• 4. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60.
• 5. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020;14:126-35.
• 6. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395:1763-70.
• 7. Kwenandar F, Japar KV, Damay V, Hariyanto TI, Tanaka M, Lugito NPH, et al. Coronavirus disease 2019 and cardiovascular system: a narrative review. Int J Cardiol Heart Vasc 2020;29:100557.
• 8. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20:355-62.
• 9. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
• 10. Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217:108509.
• 11. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan P, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8.
• 12. Chastain DB, Veve MP, Wagner JL. Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors. Antivir Ther 2019;24:459-65.
• 13. Alexander LK, Keene BW, Yount BL, Geratz JD, Small JD, Baric RS. ECG changes after rabbit coronavirus infection. J Electrocardiol 1999;32:21-32.
• 14. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-8.
• 15. Changal K, Paternite D, Mack S, Veria S, Bashir R, Patel M, et al. Coronavirus disease 2019 (COVID-19) and QTc prolongation. BMC Cardiovasc Disord 2021;21:158.
• 16. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation. Drug Saf 2001;24:323-51.
• 17. Angeli F, Spanevello A, De Ponti R ,Visca D, Marazzato J, Palmiotto G, et al. Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med 2020;78:101-6.
• 18. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation 2020;142:342-53.
• 19. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S,Bisogno S, et al. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med 2013;24:368-74.
• 20. Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-inflammatory parameters in COVID-19 cases: a systematic review and meta-analysis. Front Med (Lausanne) 2020;7:301.
• 21. Alareedh M, Nafakhi H, Shaghee F, Nafakhi A. Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID-19 pneumonia. Ann Noninvasive Electrocardiol 2021;26:e12824.
• 22. Farré N, Mojón D, Llagostera M, Belarte-Tornero LC, Calvo-Fernandez A, Valles E, et al. Prolonged QT interval in SARS-CoV-2 infection: prevalence and prognosis. J Clin Med 2020;9:2712.
• 23. Ay MO, Kozaci N, Ay OO, Kaya H, Bulut M, Yuksel M, et al. QTc interval and electrocardiographic findings of COVID-19 patients. Ann Clin Anal Med 2021;12:1031-6.
• 24. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol 2020;31:1003-8.
• 25. Krittanawong C, Kumar A, Hahn J, Wang Z, Zhang H, Sun T, et al. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis 2020;10:479-89.
• 26. Diaz-Arocutipa C, Brañez-Condorena A, Hernandez AV. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2021;30:694-706.
• 27. Mahendra M, Nuchin A, Kumar R, Shreedhar S, Mahesh PA. Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study. Adv Respir Med 2021;89:135-44.